Contineum Therapeutics (CTNM) Equity Average (2023 - 2025)
Contineum Therapeutics has reported Equity Average over the past 3 years, most recently at $175.9 million for Q3 2025.
- Quarterly results put Equity Average at $175.9 million for Q3 2025, down 17.74% from a year ago — trailing twelve months through Sep 2025 was $175.9 million (down 17.74% YoY), and the annual figure for FY2024 was $65.1 million, changed.
- Equity Average for Q3 2025 was $175.9 million at Contineum Therapeutics, down from $178.1 million in the prior quarter.
- Over the last five years, Equity Average for CTNM hit a ceiling of $213.9 million in Q3 2024 and a floor of -$76.4 million in Q2 2023.
- Median Equity Average over the past 3 years was $123.4 million (2024), compared with a mean of $76.3 million.
- Biggest five-year swings in Equity Average: surged 466.91% in 2024 and later decreased 17.74% in 2025.
- Contineum Therapeutics' Equity Average stood at -$64.5 million in 2023, then skyrocketed by 416.31% to $204.1 million in 2024, then fell by 13.82% to $175.9 million in 2025.
- The last three reported values for Equity Average were $175.9 million (Q3 2025), $178.1 million (Q2 2025), and $191.4 million (Q1 2025) per Business Quant data.